Our Research

We are increasingly vulnerable to emerging infectious diseases, with the potential for catastrophic global health crises. Disease X may arise as a novel zoonotic virus, bacterium, fungus, or parasite, or as a mutated strain of an existing pathogen, capable of evading current diagnostics, treatments, and vaccines. Nucalix has pioneered an innovative technology, TerX™, which has the unprecedented ability to neutralize a wide range of pathogens, including those not previously encountered - the key to combating Disease X. By combining cutting-edge technology with artificial intelligence, Nucalix has developed TerX™ platform to rapidly identify, isolate, and engineer these potent medicines for human use. This platform enables the creation of both therapeutics for immediate treatment and enables vaccines for long-term prevention, as well as rapid diagnostics. We use high-throughput sequencing and screening techniques to select the most potent drug candidates. We then use machine learning and bioinformatics to optimize their potency, specificity, and safety for human use.